Several BRAF and MEK inhibitors have been approved for treatment of these melanomas, such as vemurafenib, dabrafenib, encorafernib, trametinib, binimetinib, selumetinib and cobimetinib [3,5]. Here, MAP2K7 is linked to melanoma.